144 related articles for article (PubMed ID: 2660507)
21. [Measurements of prostatic acid phosphatase and prostate specific antigen by fully automated enzyme immunoassay system--its analytical and clinical evaluation].
Matui A; Yamada T; Sugita O; Yakata M
Rinsho Byori; 1990 Jun; 38(6):693-8. PubMed ID: 1696328
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between reactivation and tumor markers in prostatic cancer].
Fuse H; Umeda K; Kazama T; Sakamoto M; Sakai T; Fujishiro Y; Mizuno I; Katayama T
Hinyokika Kiyo; 1991 Jan; 37(1):39-43. PubMed ID: 1707217
[TBL] [Abstract][Full Text] [Related]
23. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
Hamami G
Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
[TBL] [Abstract][Full Text] [Related]
25. [Changes in tumor markers following cryosurgery of prostate carcinoma].
Higaki Y; Imamura K
Hinyokika Kiyo; 1989 Feb; 35(2):265-70. PubMed ID: 2472049
[TBL] [Abstract][Full Text] [Related]
26. [Benign prostatic hypertrophy with high levels of gamma-seminoprotein (gamma-Sm), prostate specific antigen: report of two cases].
Asakawa M; Yasumoto R; Kamizuru M; Maekawa M
Hinyokika Kiyo; 1988 Dec; 34(12):2189-91. PubMed ID: 2467544
[TBL] [Abstract][Full Text] [Related]
27. [Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer].
Kamachi S; Sakurabayashi I; Kawai T
Rinsho Byori; 1984 Jul; 32(7):781-5. PubMed ID: 6389940
[No Abstract] [Full Text] [Related]
28. Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein.
Hara M; Kimura H
J Lab Clin Med; 1989 May; 113(5):541-8. PubMed ID: 2654306
[TBL] [Abstract][Full Text] [Related]
29. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of gamma-seminoprotein assay as a tumor marker].
Eto K; Ueda S
Nihon Rinsho; 1990 Feb; 48 Suppl():920-4. PubMed ID: 2192175
[No Abstract] [Full Text] [Related]
31. [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA].
Gotoh A; Mizuno Y; Takenaka A; Gohji K; Ogawa T; Arakawa S; Kamidono S; Harada K; Nagata H; Hirooka K
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):467-72. PubMed ID: 1712873
[TBL] [Abstract][Full Text] [Related]
32. [Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay].
Chichibu K; Kuroe K; Hashimoto C; Goto S
Rinsho Byori; 1995 Nov; 43(11):1153-8. PubMed ID: 8551680
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of a monoclonal antibody-based enzyme immunoassay (IQ(Bio) PAP-AELIA kit) for prostatic acid phosphatase].
Koshida K; Naito K; Hisazumi H
Hinyokika Kiyo; 1987 Oct; 33(10):1703-7. PubMed ID: 3328502
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of gamma-seminoprotein in prostate cancer.
Kuriyama M; Takeuchi T; Shinoda I; Okano M; Nishiura T
Prostate; 1986; 8(3):301-11. PubMed ID: 2422639
[TBL] [Abstract][Full Text] [Related]
35. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
36. Re: Gamma-seminoprotein--a new tumor marker in prostatic cancer?
Maier U
Br J Urol; 1991 Dec; 68(6):664. PubMed ID: 1773308
[No Abstract] [Full Text] [Related]
37. Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase.
Arai Y; Yoshiki T; Okada K; Yoshida O
Urol Int; 1989; 44(3):135-40. PubMed ID: 2473564
[TBL] [Abstract][Full Text] [Related]
38. [Serum levels of beta-seminoprotein (beta-Sm) in patients with breast cancer].
Fujimasa A; Fukushima T; Yuge S; Tanaka M; Koga T; Nishimura Y; Takeda J; Kakegawa T; Fukushima I; Yuge S
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2511-8. PubMed ID: 2175763
[TBL] [Abstract][Full Text] [Related]
39. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
Fuse H; Umeda K; Mizuno I; Katayama T
Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
[TBL] [Abstract][Full Text] [Related]
40. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer].
Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J
Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
